Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model

Cristina Martínez-García1, Adriana Izquierdo, Vidya Velagapudi

  • 1Universidad Rey Juan Carlos, Dpto. de Bioquímica, Fisiología y Genética Molecular, Avda. de Atenas s/n. 28922, Alcorcón, Madrid, Spain.

Insights

Metabolic syndrome accelerates chronic kidney disease (CKD) in POKO mice. Glucolipotoxicity exacerbates renal damage, inflammation, and fibrosis, highlighting its role in diabetic nephropathy pathogenesis.

Area of Science:

  • Nephrology
  • Metabolic Diseases
  • Genetics

Background:

  • Metabolic syndrome increases chronic kidney disease (CKD) risk via unclear mechanisms.
  • Glucolipotoxicity from obesity and diabetes is implicated in diabetic nephropathy.
  • The POKO mouse model combines PPARγ2 knockout with genetic obesity.

Purpose of the Study:

  • To investigate renal structural and functional changes in the POKO mouse model.
  • To determine the role of glucolipotoxicity in accelerated kidney disease pathogenesis.
  • To analyze blood pressure and molecular changes in POKO mice.

Main Methods:

  • Generation of the POKO mouse model (PPARγ2 KO x ob/ob).
  • Metabolic phenotyping, including assessment of hyperphagia, insulin resistance, and dyslipidemia.
  • Analysis of kidney structure, function (albumin:creatinine ratio), blood pressure, and molecular markers (p27Kip1, TGFβ, PTHrP, MCP-1).

Main Results:

  • POKO mice exhibit accelerated renal disease, characterized by increased renal hypertrophy and p27Kip1 expression.
  • Glucolipotoxicity in POKO mice leads to glomeruli damage, altered lipid metabolism, and elevated TGFβ, PTHrP, and MCP-1.
  • Renal damage is fully established by 12 weeks, suggesting glucolipotoxic effects drive pathogenesis.

Conclusions:

  • The POKO mouse is a valuable model for studying accelerated diabetic nephropathy.
  • Glucolipotoxicity significantly contributes to the pathogenesis of renal disease in this model.
  • Targeting glucolipotoxic pathways may offer therapeutic strategies for CKD in metabolic syndrome.